Literature DB >> 10361876

T cell costimulatory blockade: new therapies for transplant rejection.

H Gudmundsdottir1, L A Turka.   

Abstract

Optimal T cell responses occur when T cells receive both antigen-specific signals through the T cell receptor and non-antigen-specific costimulatory signals through accessory cell surface molecules. The best understood costimulatory receptor is CD28. Signals through the T cell receptor and CD28 cooperatively induce cytokine gene expression and promote T cell proliferation and survival. Negative signals delivered through a related cell surface receptor, cytotoxic T lymphocyte antigen (CTLA-4), act to terminate immune responses and are required for normal immune homeostasis. This article reviews T cell costimulation, including the CD28/CTLA-4 system and other potential costimulatory pathways (such as CD40/CD154), the role of these pathways in normal immune responses, and the potential for the inhibition of these pathways to induce transplantation tolerance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361876     DOI: 10.1681/ASN.V1061356

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  11 in total

1.  Blocking B7 and CD40 co-stimulatory molecules decreases antiviral T cell activity.

Authors:  J Vermeiren; J L Ceuppens; H Haegel-Kronenberger; M De Boer; L Boon; S W Van Gool
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

2.  Lymphotoxin-beta receptor blockade induces inflammation and fibrosis in tolerized cardiac allografts.

Authors:  Y Nakayama; J S Bromberg
Journal:  Am J Transplant       Date:  2012-05-17       Impact factor: 8.086

3.  Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation.

Authors:  Vanessa M Hubbard; Jeffrey M Eng; Teresa Ramirez-Montagut; Kartono H Tjoe; Stephanie J Muriglan; Adam A Kochman; Theis H Terwey; Lucy M Willis; Rafaella Schiro; Glen Heller; George F Murphy; Chen Liu; Onder Alpdogan; Marcel R M van den Brink
Journal:  Blood       Date:  2005-06-14       Impact factor: 22.113

4.  Human allograft acceptance is associated with immune regulation.

Authors:  A M VanBuskirk; W J Burlingham; E Jankowska-Gan; T Chin; S Kusaka; F Geissler; R P Pelletier; C G Orosz
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

5.  Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs.

Authors:  Iryna A Isakova; Jason Dufour; Calvin Lanclos; Julie Bruhn; Donald G Phinney
Journal:  Exp Hematol       Date:  2010-07-01       Impact factor: 3.084

6.  Immune response modulation by recombinant peptides expressed in virus-like particles.

Authors:  E V Svirshchevskaya; L Alekseeva; A Marchenko; N Viskova; T M Andronova; S V Benevolenskii; V P Kurup
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

7.  Analysis of cytokine gene polymorphisms in recipient's matched with living donors on acute rejection after renal transplantation.

Authors:  Parmeet Kaur Manchanda; Rama Devi Mittal
Journal:  Mol Cell Biochem       Date:  2007-12-29       Impact factor: 3.396

8.  Human Chorionic Villous Mesenchymal Stem Cells Modify the Functions of Human Dendritic Cells, and Induce an Anti-Inflammatory Phenotype in CD1+ Dendritic Cells.

Authors:  F M Abomaray; M A Al Jumah; B Kalionis; A S AlAskar; S Al Harthy; D Jawdat; A Al Khaldi; A Alkushi; B A Knawy; M H Abumaree
Journal:  Stem Cell Rev Rep       Date:  2015-06       Impact factor: 5.739

9.  Allergen-specific subcutaneous immunotherapy in allergic asthma: immunologic mechanisms and improvement.

Authors:  Yousef A Taher; Paul A J Henricks; Antoon J M van Oosterhout
Journal:  Libyan J Med       Date:  2010-06-21       Impact factor: 1.657

10.  STAT-1 decoy oligodeoxynucleotide inhibition of acute rejection in mouse heart transplants.

Authors:  Tomislav Stojanovic; Andreas H Wagner; Shijun Wang; Eva Kiss; Nicolas Rockstroh; Jens Bedke; Hermann-Josef Gröne; Markus Hecker
Journal:  Basic Res Cardiol       Date:  2009-04-08       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.